Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series
In conclusion, our study suggests that nivolumab monotherapy is well-tolerated and may be an effective salvage therapy for BRCA mutation carriers with recurrent epithelial ovarian, fallopian tubal, and primary peritoneal cancers.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
More News: Cancer | Cancer & Oncology | Epithelial Cancer | Gastroschisis Repair | Genetics | Hypothyroidism | Immunotherapy | Ovarian Cancer | Ovaries | Peritoneal Cancer | Study | Toxicology | Women